[go: up one dir, main page]

IT1397011B1 - Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne. - Google Patents

Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.

Info

Publication number
IT1397011B1
IT1397011B1 ITTO2009A000782A ITTO20090782A IT1397011B1 IT 1397011 B1 IT1397011 B1 IT 1397011B1 IT TO2009A000782 A ITTO2009A000782 A IT TO2009A000782A IT TO20090782 A ITTO20090782 A IT TO20090782A IT 1397011 B1 IT1397011 B1 IT 1397011B1
Authority
IT
Italy
Prior art keywords
vehiculation
oligonucleotids
nanoparticle
medication
therapeutic
Prior art date
Application number
ITTO2009A000782A
Other languages
English (en)
Inventor
Alessandra Ferlini
Alessandro Medici
Katia Sparnacci
Daniela Perrone
Luisa Tondelli
Paola Rimessi
Michele Laus
Original Assignee
Univ Ferrara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ferrara filed Critical Univ Ferrara
Priority to ITTO2009A000782A priority Critical patent/IT1397011B1/it
Priority to EP10771208.5A priority patent/EP2488165B1/en
Priority to PCT/IB2010/054618 priority patent/WO2011045747A1/en
Publication of ITTO20090782A1 publication Critical patent/ITTO20090782A1/it
Application granted granted Critical
Publication of IT1397011B1 publication Critical patent/IT1397011B1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ITTO2009A000782A 2009-10-14 2009-10-14 Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne. IT1397011B1 (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ITTO2009A000782A IT1397011B1 (it) 2009-10-14 2009-10-14 Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.
EP10771208.5A EP2488165B1 (en) 2009-10-14 2010-10-12 Nanoparticle of the core-shell type suitable for delivering therapeutic oligonucleotides to target tissues and the use thereof for the preparation of a medicament for treating duchenne muscular dystrophy
PCT/IB2010/054618 WO2011045747A1 (en) 2009-10-14 2010-10-12 Nanoparticle of the core-shell type suitable for delivering therapeutic oligonucleotides to target tissues and the use thereof for the preparation of a medicament for treating duchenne muscular dystrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITTO2009A000782A IT1397011B1 (it) 2009-10-14 2009-10-14 Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.

Publications (2)

Publication Number Publication Date
ITTO20090782A1 ITTO20090782A1 (it) 2011-04-15
IT1397011B1 true IT1397011B1 (it) 2012-12-20

Family

ID=42098064

Family Applications (1)

Application Number Title Priority Date Filing Date
ITTO2009A000782A IT1397011B1 (it) 2009-10-14 2009-10-14 Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.

Country Status (3)

Country Link
EP (1) EP2488165B1 (it)
IT (1) IT1397011B1 (it)
WO (1) WO2011045747A1 (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3808845A1 (en) 2004-06-28 2021-04-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
BR122020021379B1 (pt) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
DK2499249T3 (en) 2009-11-12 2018-12-03 Univ Western Australia ANTISENCE MOLECULES AND PROCEDURES FOR TREATING PATHOLOGIES
AU2014236140B2 (en) 2013-03-14 2019-10-03 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
WO2014144978A2 (en) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
JP2024505151A (ja) * 2021-01-12 2024-02-05 ノースウェスタン ユニバーシティ 脂質ナノ粒子球状核酸

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2407501A (en) * 2003-11-03 2005-05-04 Ist Superiore Sanita Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell

Also Published As

Publication number Publication date
ITTO20090782A1 (it) 2011-04-15
EP2488165B1 (en) 2014-07-23
EP2488165A1 (en) 2012-08-22
WO2011045747A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
Liu et al. pH-sensitive nano-systems for drug delivery in cancer therapy
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
LT2170396T (lt) Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui
GB0715087D0 (en) Drug combinations for the treatment of duchenne muscular dystrophy
EP2391419A4 (en) ACTIVE INFUSION IN THE REAR EYE SEGMENT
IL236504A0 (en) Oligonucleotide for the treatment of muscular dystrophy patients
IL255752B (en) Compounds, pharmaceutical compositions comprising the same and uses thereof for treating cardiovasclar disease, an inflammatory disease or cancer
IT1397011B1 (it) Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.
HUE044384T2 (hu) Ultrafinom nanorészecskék, melyek egy fémkomplexeket tartalmazó funkcionalizált poliorganosziloxán mátrixot tartalmaznak; eljárás azok elõállítására, és alkalmazásuk gyógyászati képalkotásban
EP2611421A4 (en) TUMOR PLAYING OF A MEDICINAL PRODUCT ON NANOPARTICLE BASIS
ITTO20110628A1 (it) Composizione farmaceutica di combinazione e metodi per trattare patologie funzionali o stati patologici del tratto gastrointestinale
EP2509421A4 (en) ACTIVE COMPOSITION OF TEMOZOLOMIDE FOR SYSTEMIC CANCER TREATMENT
LT4104824T (lt) Kompozicijos, skirtos panaudoti taikant pacientams su didele širdies ir kraujagyslių ligos rizika antsvorio ir nutukimo gydymo būdą
CL2012003340A1 (es) Composicion farmaceutica de administracion oral de bendamustina y su uso en el tratamiento oral de una condicion medica seleccionada de leucemia linfocitica cronica, cancer de mama, entre otras.
BRPI1008517A2 (pt) direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.
IT1403293B1 (it) Apparecchiatura ad aghi per la somministrazione transdermica di farmaci.
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
DOP2011000031A (es) Vacuna contra el virus del papiloma humano(hpv)
EP2473039A4 (en) PERMANENT TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINISATION
ITTO20090487A1 (it) Oligonucleotidi antisenso atti ad indurre lo skipping esonico e loro impiego come medicamento per il trattamento della distrofia muscolare di duchenne (dmd)
EP2453742A4 (en) IBUPROFEN TREATMENT INTRAVENOUSLY
EP2632939A4 (en) CANCER-TREATED PEPTIDES AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS
WO2011079213A9 (en) Treating critically ill patients with intravenous ibuprofen
LT2702033T (lt) 3-karboksi-n-etil-n,n-dimetilpropan-1-amino druskos panaudojimas kardiovaskuliarinių ligų gydyme
FR2943671B1 (fr) Composes anticancereux,leur preparation et leur application en therapeutique